Know Cancer

or
forgot password

Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors


Phase 1/Phase 2
18 Years
N/A
Not Enrolling
Both
Metastatic Solid Tumors

Thank you

Trial Information

Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors


Inclusion Criteria:



- Patients with measurable metastatic disease or disease resistant to chemotherapy or
with minimal residual disease at high risk to relapse.

Exclusion Criteria:

- Karnofsky less than 60%. Unrelated condition requiring the use of any cytotoxic
agents or immunosuppressive agents which may interfere with optimal immune response.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label

Outcome Measure:

Investigate the feasibility of anti-tumor immune response by allogeneic tumor cell vaccine using tumor cells that share MHC determinants with the patient.

Principal Investigator

shimon slavin, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

The International Center for Cell Therapy & Cancer Immunotherapy (CTCI)

Authority:

Israel: Israeli Health Ministry Pharmaceutical Administration

Study ID:

100798-HMO-CTIL

NCT ID:

NCT00148993

Start Date:

July 1998

Completion Date:

July 2005

Related Keywords:

  • Metastatic Solid Tumors
  • Tumor cell vaccine
  • Neoplasms

Name

Location